A Multicenter, Open-Label, Noncomparative Phase 1-2 Clinical And Pharmacokinetic Study Of Oral PD 0325901 In Patients With Advanced Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 12 Sep 2013
At a glance
- Drugs PD 325901 (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 06 Jul 2011 Planned end date changed from 1 Jul 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 16 Feb 2010 Planned end date changed from 1 Feb 2010 to 1 Aug 2010 as reported by ClinicalTrials.gov.
- 30 Dec 2008 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.